Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Google Scholar
Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer Statist. CA Cancer J. Clin. 74, 12–49 (2024).
Google Scholar
Li, C. J. et al. The molecular mechanism of epithelial-mesenc hymal transition for breast carcinogenesis. Biomolecules 9, 476 (2019).
Google Scholar
Tzeng, Y. T., et al. Integrated analysis of pivotal biomarker of LSM1, immune cell infiltration and therapeutic drugs in breast cancer. J. Cell Mol. Med. 26, 4007–4020 (2022).
Google Scholar
Müller, V. et al. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: a systematic literature review. Cancer Treat. Rev. 115, 102527 (2023).
Google Scholar
Gluz, O. & Graeser, M. Molecular profiling in Early ER + breast cancer to aid systemic therapy decisions. Curr. Oncol. Rep. 25, 491–500 (2023).
Google Scholar
Tzeng, Y. T. et al. Breast cancer organoids derived from patients: a platform for tailored drug screening. Biochem Pharm. 217, 115803 (2023).
Google Scholar
Hammond, M. E. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784–2795 (2010).
Google Scholar
Nielsen, T. O. et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 113, 808–819 (2021).
Google Scholar
Cardoso, F. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717–729 (2016).
Google Scholar
Qian, Y. et al. Prognostic cancer gene expression signatures: current status and challenges. Cells 10, 648 (2021).
Google Scholar
Jézéquel, P. et al. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Res. 21, 65 (2019).
Google Scholar
Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78 (2004).
Google Scholar
Barriga, V. et al. The complex interaction between the tumor micro-environment and immune checkpoints in breast cancer. Cancers 11, 1205 (2019).
Google Scholar
Queen, M. M. et al. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 65, 8896–8904 (2005).
Google Scholar
Treffers, L. W. et al. Neutrophils in cancer. Immunol. Rev. 273, 312–328 (2016).
Google Scholar
Gelsomino, L. et al. Leptin signaling contributes to aromatase inhibitor resistant breast cancer cell growth and activation of macrophages. Biomolecules 10, 543 (2020).
Google Scholar
Hughes, R. et al. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 75, 3479–3491 (2015).
Google Scholar
de Vicente, J. C. et al. Lectin-like transcript-1 (LLT1) expression in oral squamous cell carcinomas: prognostic significance and relationship with the tumor immune microenvironment. Int. J. Mol. Sci. 25, 4314 (2024).
Google Scholar
Lin, S. et al. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors. Genome Med. 16, 60 (2024).
Google Scholar
Tien, F. M. et al. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. J. Biomed. Sci. 30, 3 (2023).
Google Scholar
Yin, J. et al. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. Front. Immunol. 14, 1325615 (2023).
Google Scholar
Pearson, J. C., Lemons, D. & McGinnis, W. Modulating Hox gene functions during animal body patterning. Nat. Rev. Genet 6, 893–904 (2005).
Google Scholar
Shah, N. & Sukumar, S. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 10, 361–371 (2010).
Google Scholar
Bhatlekar, S., Fields, J. Z. & Boman, B. M. HOX genes and their role in the development of human cancers. J. Mol. Med.92, 811–823 (2014).
Google Scholar
Inamura, K. et al. HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells. Anticancer Res. 28, 2121–2127 (2008).
Google Scholar
Gonzalez-Herrera, A. et al. Increased expression of HOXB2 and HOXB13 proteins is associated with HPV infection and cervical cancer progression. Asian Pac. J. Cancer Prev. 16, 1349–1353 (2015).
Google Scholar
Xu, F. et al. Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma. Cell Commun. Signal 18, 17 (2020).
Google Scholar
Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019).
Google Scholar
Oh, J. H. et al. The homeoprotein HOXB2 limits triple-negative breast carcinogenesis via extracellular matrix remodeling. Int J. Biol. Sci. 20, 1045–1063 (2024).
Google Scholar
Yu, H. Y. & Pan, S. S. MiR-202-5p suppressed cell proliferation, migration and invasion in ovarian cancer via regulating HOXB2. Eur. Rev. Med. Pharm. Sci. 24, 2256–2263 (2020).
Boimel, P. J., Cruz, C. & Segall, J. E. A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer. Genomics 98, 164–172 (2011).
Google Scholar
Blücher, C. & Stadler, S. C. Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast cancer growth and progression. Front Endocrinol.8, 293 (2017).
Madak-Erdogan, Z. et al. Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling. Cancer Res. 79, 2494–2510 (2019).
Google Scholar
George Warren, W. et al. The emerging role of fatty acid binding protein 5 (FABP5) in cancers. Drug Discov. Today 28, 103628 (2023).
Google Scholar
Jiang, Q. et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 16, 513–533 (2005).
Google Scholar
Iwata, M. et al. Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. Blood 100, 1318–1325 (2002).
Google Scholar
Al-Rawi, M. A. et al. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur. J. Cancer 40, 494–502 (2004).
Google Scholar
Fernandez-Botran, R. Soluble cytokine receptors: basic immunology and clinical applications. Crit. Rev. Clin. Lab Sci. 36, 165–224 (1999).
Google Scholar
Fernandez-Botran, R., Crespo, F. A. & Sun, X. Soluble cytokine receptors in biological therapy. Expert Opin. Biol. Ther. 2, 585–605 (2002).
Google Scholar
Lundström, W. et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc. Natl. Acad. Sci. USA 110, E1761–E1770 (2013).
Google Scholar
Lee, B. & Hong, C. The role of soluble common gamma chain in autoimmune disease. Anat. Cell Biol. 48, 10–15 (2015).
Google Scholar
Lundmark, F. et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39, 1108–1113 (2007).
Google Scholar
Todd, J. A. et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39, 857–864 (2007).
Google Scholar
McKay, F. C. et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes Immun. 9, 1–6 (2008).
Google Scholar
Crawley, A. M., Faucher, S. & Angel, J. B. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J. Immunol. 184, 4679–4687 (2010).
Google Scholar
Park, S. L. et al. p27KIP1 is involved in ERK1/2-mediated MMP-9 expression via the activation of NF-κB binding in the IL-7-induced migration and invasion of 5637 cells. Int J. Oncol. 44, 1349–1356 (2014).
Google Scholar
Chen, D. et al. Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. Front Immunol. 12, 747324 (2021).
Google Scholar
Delgado-Martin, C. et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 31, 2568–2576 (2017).
Google Scholar
Ribeiro, D. et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2, 2199–2213 (2018).
Google Scholar
Barata, J. T. et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med 200, 659–669 (2004).
Google Scholar
Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 7, 1238–1247 (2017).
Google Scholar
Zhao, Z. et al. Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. Biomed. Res Int 2020, 4795171 (2020).
Google Scholar
Huang, B. et al. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Oncoimmunology 9, 1684127 (2020).
Google Scholar
Noh, K. E. et al. TGF-β/IL-7 Chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma. Int. J. Mol. Sci. 22, 8706 (2022).
Yasunaga, M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 64, 1–12 (2020).
Google Scholar
Penaranda, C. et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc. Natl. Acad. Sci. USA 109, 12668–12673 (2012).
Google Scholar
Hartgring, S. A. et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 62, 2716–2725 (2010).
Google Scholar
Yasunaga, M., Manabe, S. & Matsumura, Y. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease. Sci. Rep. 7, 10735 (2017).
Google Scholar
Akkapeddi, P. et al. A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Leukemia 33, 2155–2168 (2019).
Google Scholar
Senkevitch, E. et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations. Oncotarget 9, 22605–22617 (2018).
Google Scholar
Maude, S. L. et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120, 3510–3518 (2012).
Google Scholar
Oda, Y. et al. Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. J. Biol. Chem. 268, 5929–5939 (1993).
Google Scholar
Barondes, S. H. et al. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269, 20807–20810 (1994).
Google Scholar
Yasinska, I. M. et al. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front. Immunol. 10, 1594 (2019).
Google Scholar
Chen, Z. et al. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. Faseb J.35, e21401 (2021).
Google Scholar
Seifert, A. M. et al. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Oncogene 39, 3102–3113 (2020).
Google Scholar
Yuan, F. et al. Molecular and clinical characterization of Galectin-9 in glioma through 1027 samples. J. Cell Physiol. 235, 4326–4334 (2020).
Google Scholar
Nakajima, R. et al. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. J. Dermatol Sci. 96, 134–142 (2019).
Google Scholar
Wdowiak, K. et al. Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncol. Lett. 17, 1019–1029 (2019).
Google Scholar
Wu, C. et al. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 41, 270–282 (2014).
Google Scholar
Irie, A. et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 11, 2962–2968 (2005).
Google Scholar
Yamauchi, A. et al. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J. 12, S196–S200 (2006).
Google Scholar
